评估SLC6A2和CYP2D6多态的SLC6A2和CYP2D6多态对在注意力缺陷和多动性障碍中治疗阿托莫克的影响
Ismail Hasan Kole1, Pınar Vural2, Beste Yurdacan3
1Department of Child and Adolescent Psychiatry, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye. hasankole@uludag.edu.tr.
在ADHD患者中,SLC6A2和CYP2D6的遗传变异会影响阿托莫丁的反应. 特定的基因型与治疗有效性和副作用严重程度相关,有助于个性化ADHD治疗.
科学领域:
- 药物遗传学 药物遗传学
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
背景情况:
- 有限的数据存在于SLC6A2和CYP2D6多态和ATX治疗反应在ADHD之间的关系.
- 这项研究调查了SLC6A2和CYP2D6中关键单核酸多态 (SNPs) 对ATX在注意力缺陷和多动性障碍 (ADHD) 疗效的影响.
研究的目的:
- 评估SLC6A2和CYP2D6中顶线SNP对ADHD中ATX治疗反应的影响.
- 分析CYP2D6SNP与ATX相关副作用的严重程度之间的关联.
主要方法:
- 对十个SNP (SLC6A2中的六个,CYP2D6中的四个) 的基因定型对34名符合纳入标准的ADHD患者进行.
- 对ATX治疗的反应与基因型相关;对37名患者的CYP2D6SNP和副作用严重程度进行了分析.
主要成果:
- 所有六种研究的SLC6A2多态都与ATX治疗反应有关.
- 在 rs3785143 (p=0.026) 的同卵性"C"等位基因携带者中观察到对立挑性障碍症状的临床改善.
- 较高的CGI副作用严重性得分与CYP2D6中rs1065852多态的"TT"基因型有关 (p=0.043).
结论:
- SLC6A2和CYP2D6多态的基因型可能会显著影响ADHD的ATX治疗反应.
- 这些发现表明药物遗传学在预测ATX疗效和副作用概况方面发挥了作用,可能引导个性化的ADHD治疗策略.
更多相关视频
09:43The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents
Published on: August 10, 2014
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
